JP2024045291A5 - - Google Patents

Download PDF

Info

Publication number
JP2024045291A5
JP2024045291A5 JP2024008397A JP2024008397A JP2024045291A5 JP 2024045291 A5 JP2024045291 A5 JP 2024045291A5 JP 2024008397 A JP2024008397 A JP 2024008397A JP 2024008397 A JP2024008397 A JP 2024008397A JP 2024045291 A5 JP2024045291 A5 JP 2024045291A5
Authority
JP
Japan
Prior art keywords
alkyl
amino
thiazole
carboxamide
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024008397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024045291A (ja
JP7785108B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/045183 external-priority patent/WO2019028362A1/en
Application filed filed Critical
Publication of JP2024045291A publication Critical patent/JP2024045291A/ja
Publication of JP2024045291A5 publication Critical patent/JP2024045291A5/ja
Application granted granted Critical
Publication of JP7785108B2 publication Critical patent/JP7785108B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024008397A 2017-08-04 2024-01-24 血漿カリクレインの阻害剤およびその使用 Active JP7785108B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762541403P 2017-08-04 2017-08-04
US62/541,403 2017-08-04
PCT/US2018/045183 WO2019028362A1 (en) 2017-08-04 2018-08-03 INHIBITORS OF PLASMATIC KALLIKREIN AND USES THEREOF
JP2020505842A JP7210540B2 (ja) 2017-08-04 2018-08-03 血漿カリクレインの阻害剤およびその使用
JP2023002547A JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023002547A Division JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用

Publications (3)

Publication Number Publication Date
JP2024045291A JP2024045291A (ja) 2024-04-02
JP2024045291A5 true JP2024045291A5 (enExample) 2024-04-24
JP7785108B2 JP7785108B2 (ja) 2025-12-12

Family

ID=63209746

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020505842A Active JP7210540B2 (ja) 2017-08-04 2018-08-03 血漿カリクレインの阻害剤およびその使用
JP2023002547A Active JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用
JP2024008397A Active JP7785108B2 (ja) 2017-08-04 2024-01-24 血漿カリクレインの阻害剤およびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020505842A Active JP7210540B2 (ja) 2017-08-04 2018-08-03 血漿カリクレインの阻害剤およびその使用
JP2023002547A Active JP7427812B2 (ja) 2017-08-04 2023-01-11 血漿カリクレインの阻害剤およびその使用

Country Status (5)

Country Link
US (3) US11168083B2 (enExample)
EP (2) EP4494698A3 (enExample)
JP (3) JP7210540B2 (enExample)
AU (3) AU2018311976B2 (enExample)
WO (1) WO2019028362A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4494698A3 (en) 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
US20230312542A1 (en) * 2020-03-31 2023-10-05 Mitsubishi Tanabe Pharma Corporation Hydroxypyrrolidine derivative and medicinal application thereof
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response
WO2024059186A1 (en) * 2022-09-15 2024-03-21 Takeda Pharmaceutical Company Limited N-((isoquinolin-6-yl)methyl)-1h-pyrazole-4-carboxamid derivatives as plasma kallikrein inhibitors for the treatment of hereditary angioedema
CN116063215A (zh) * 2023-02-23 2023-05-05 南京安淮创新药物研究院有限公司 一种4-氨基-l-脯氨酸的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3676677B2 (ja) 1998-06-30 2005-07-27 ファイザー・プロダクツ・インク 炎症性疾患、自己免疫疾患および呼吸疾患の治療において有用なvla−4依存性細胞結合の非ペプチジル阻害薬
US7622496B2 (en) * 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
WO2010015090A1 (en) * 2008-08-07 2010-02-11 Aegera Therapeutics Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US9079880B2 (en) * 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
CN104185624B (zh) * 2012-02-24 2016-10-12 弗·哈夫曼-拉罗切有限公司 抗病毒化合物
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
ES2931460T3 (es) 2015-02-27 2022-12-29 Verseon Int Corporation Compuestos de pirazol sustituido como inhibidores de serina proteasa
CA3290174A1 (en) * 2015-03-30 2026-03-02 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017001936A2 (en) * 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
FI4019022T3 (fi) 2015-10-01 2024-04-19 Biocryst Pharm Inc Ihmisen plasman kallikreiinin estäjiä
EP4494698A3 (en) 2017-08-04 2025-04-23 Takeda Pharmaceutical Company Limited Inhibitors of plasma kallikrein and uses thereof
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN114728962B (zh) * 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) * 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
EP4136091B1 (en) * 2020-04-17 2025-05-28 Takeda Pharmaceutical Company Limited Forms and compositions of inhibitors of plasma kallikrein

Similar Documents

Publication Publication Date Title
JP2023040213A5 (enExample)
DE60316440T2 (de) Benzo-kondensierte heteroarylamid-derivative von thienopyridinen nützlich als therapeutische agentien, entsprechende pharmazeutische zusammensetzungen, und methoden für ihre verwendung
JP2020529998A5 (enExample)
JP2021534240A5 (enExample)
TWI501963B (zh) 特定胺基-嗒類,與其組成物,及其使用方法
CA2869337C (en) Cyclic amides as metap-2 inhibitors
AU2001294117B2 (en) Combination use of acetylcholinesterase inhibitors and GABAA inverse agonists for the treatment of cognitive disorders
TWI298066B (en) Diamine derivatives
JP5852099B2 (ja) ある種のアミノ−ピリミジン、その組成物、及びそれを用いるための方法
KR20180043343A (ko) 의학적 질병의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 화합물
JP2020531498A5 (enExample)
HRP20192323T1 (hr) Novi derivati dihidrokinolin-2-ona
WO2008052671A2 (de) Kombinationstherapie substituierter oxazolidinone
KR20170031669A (ko) 치환된 우레아 유도체 및 이의 약제학적 용도
CN101678107A (zh) 用于治疗杜兴型肌营养不良的药物组合物
HRP20171075T1 (hr) Piridiloksiindol-inhibitori za vegf-r2 i njihova uporaba u liječenju bolesti
AU2013273222A1 (en) Benzimidazole-proline derivatives
RU2006126663A (ru) Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций
JP2015537003A (ja) 精神分裂病を処置するための方法および組成物
WO2007039134A1 (de) Kombinationstherapie mit substituierten oxazolidinonen zur prophylaxe und behandlung von cerebralen durchblutungsstörungen
JP2018510140A (ja) アルキニルアルコール及び使用方法
US20170015654A1 (en) Pyridazine compound
JP2021535137A5 (enExample)
JP2025542413A (ja) プロテインチロシンキナーゼ阻害剤及びその医療上の使用
JP7356352B2 (ja) 眼疾患の予防方法又は処置方法